ТАРҚАЛГАН ПРОСТАТА БЕЗИ САРАТОНИДА ГОРМОНАЛ ТЕРАПИЯНИ СОЛИШТИРМА-ҚИЁСИЙ САМАРАДОРЛИГИ

1. Bishr M., Boehm K., Trudeau V. Medical management of benign prostatic hyperplasia: Results from a population-based study. // Can Urol Assoc J. -2016. - 10(1-2). - 55-59. 2. Foley C., Mitsiades N. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. // Horm Cancer. – 2016. - 7(2). - 84-103. 3. Chopra S., Rashid P. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions. // Aust Fam Physician. – 2015. - 44(5). - 302-305. 4. Chandrasekar T., Yang J.C., Gao A.C., Evans C.P. Mechanisms of resistance in castrationresistant prostate cancer (CRPC). // Transl Androl Urol. – 2015. - 4(3). - 365-380. 5. Soga N., Kageyama T., Ogura Y., Yamada T., Hayashi N. Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl. // Curr Urol. – 2016. - 9(1). - 31-35. 6. Sun M., Choueiri T.K., Hamnvik O.R. et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of AndrogenDeprivation Therapy. // JAMA Oncol. – 2015. – 23. - 1-8. 7. Hingorani M., Dixit S., Bashir F. et al. Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports. // Cancer Biol Med. – 2014. - 11(4). - 277-280.